Arthritis
A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities have also led to the growth in the market. The global rheumatology therapeutics market will rise at a lackluster CAGR of 2.7% from 2017 to 2025 to become worth US$ 52.96 bn by 2025 from US$41.88 bn in 2016. Nearly 20% of aged people who suffer a hip fracture die within a year. One out of every two women over 50 will have an osteoporosis-related fracture in their lifetime, with risk of fracture increasing with age. The global rheumatology therapeutics market is projected to be driven by the increasing geriatric population in developed countries. Also according to world arthritis day, more than 120 million people in European Union are affected by some of the forms of arthritis. The growing geriatric population in developed countries is likely to be key driving factor for global rheumatology therapeutics market. Geriatric Rheumatology is the branch of prescription that studies rheumatologic disarranges in matured. It is likewise called Gerontorheumatology.